Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Ablation & Embolization
Oncothermia
What oncothermia is, how modulated electro-hyperthermia targets malignant cells using radiofrequency energy, what clinical trials show about its role alongside chemotherapy and radiotherapy, approximate treatment costs in Turkey compared with the UK, US and Germany, who qualifies for treatment, typical session schedules, realistic expectations on follow-up imaging, potential side effects and how to choose an accredited oncology centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Ablation & Embolization
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Oncothermia
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Oncothermia in Turkey: what is modulated electro-hyperthermia and how it works
Oncothermia, also known as modulated electro-hyperthermia (mEHT), is a specialised hyperthermia method used as a complementary treatment for solid tumours. The technique transmits a controlled 13.56-megahertz radiofrequency current between two capacitive electrodes placed across the tumour site. Unlike conventional hyperthermia, which heats tissue volumes indiscriminately, oncothermia uses amplitude-modulated electric fields to target malignant cells selectively based on their distinct metabolic and dielectric properties. Patients exploring complementary cancer care can consult our guide to oncology treatments in Turkey for multidisciplinary therapy options.
Malignant cells exhibit higher glycolysis and ionic conductivity, forming a path of least electrical resistance. The modulated field concentrates in this extracellular fluid, warming cancer cell membranes to 40–42.5°C while sparing healthy tissue. This heating induces cellular stress, damages membranes, and promotes apoptosis. In Turkey, hospitals provide oncothermia within integrated cancer units alongside systemic therapies.
How does an oncothermia session work step by step?
An oncothermia session follows an outpatient clinical protocol designed for patient comfort and precise energy delivery. The procedure requires no general anaesthesia or surgical incisions, allowing you to remain awake throughout.
- Pre-treatment evaluation: The oncology team checks blood pressure, heart rate, and recent blood counts to confirm treatment readiness.
- Patient positioning: You recline comfortably on an ergonomic couch fitted with a built-in lower electrode. A flexible, water-cooled electrode is positioned over the tumour area.
- Capacitive coupling: A circulating water bolus contours to the skin surface, preventing superficial burns and maintaining steady electrical impedance.
- Modulated energy delivery: The device delivers 13.56-megahertz radiofrequency energy, automatically adjusting power between 40 and 150 watts based on tissue feedback.
- Continuous monitoring: Clinical staff track skin temperature and comfort throughout the 60- to 90-minute session while you rest.
- Immediate discharge: Once completed, the electrodes are removed, skin is inspected, and you can resume normal light activities immediately.
Does oncothermia actually work? What the clinical evidence shows
Oncothermia is an established adjunct therapy rather than a standalone cure. Clinical guidelines from hyperthermia research groups emphasise that it works synergistically with standard chemotherapy and radiotherapy, rather than replacing conventional medical protocols.
Published clinical trials and observational studies across solid tumours—such as glioblastoma, cervical carcinoma, lung cancer, and colorectal metastases—highlight three primary mechanisms:
- Radiosensitisation: Mild thermal heating dilates tumour microvessels, improving oxygenation. Because radiotherapy depends on oxygen to generate tumour-killing free radicals, heating directly enhances radiation efficacy.
- Chemosensitisation: Increased perfusion enhances drug penetration into poorly vascularised tumour cores. Heat also increases cell membrane permeability and suppresses DNA repair enzymes in malignant cells.
- Antitumour immune response: Thermal stress stimulates the release of heat-shock proteins (such as HSP70 and calreticulin) on tumour cell surfaces, facilitating immune recognition by dendritic cells and cytotoxic T-lymphocytes.
However, evidence boundaries must be respected. While phase II data demonstrate improved local control and progression-free survival in selected patient groups, large-scale phase III randomised trials remain limited for certain tumour stages. Oncothermia cannot cure metastatic cancer alone, and responsible clinicians will never present it as an alternative to standard oncology care.
Oncothermia cost in Turkey compared with the UK, US and Germany
The cost of oncothermia depends on the number of sessions, tumour location, concurrent oncology consultations, and diagnostic imaging. In Turkey, treatment cycles are priced competitively compared with private European and American centres.
The table below provides approximate cost ranges per session and for a standard 10-session protocol. These figures represent general hospital averages and are not individual quotes.
| Country | Approximate cost per session | Approximate cost (10-session cycle) |
|---|---|---|
| Turkey | €200 – €500 | €2,000 – €4,800 |
| United Kingdom | €600 – €1,400 | €6,000 – €13,500 |
| United States | €800 – €2,200 | €7,500 – €20,000 |
| Germany | €400 – €950 | €4,000 – €9,000 |
What influences the total price includes the number of sessions recommended by the multidisciplinary tumour board, synchronization with chemotherapy infusions, and baseline MRI or PET-CT scans. Turkish medical packages typically include specialist consultations, treatment planning, electrode sessions, routine blood monitoring, and transfers. Each clinic confirms pricing through a formal written quote.
Oncothermia, conventional hyperthermia or radiofrequency ablation?
Different thermal oncology treatments use distinct technical mechanisms and serve different clinical purposes. Understanding these differences helps clarify why a multidisciplinary team selects one modality over another.
| Treatment modality | Mechanism and target | Best suited to | Typical limits |
|---|---|---|---|
| Oncothermia (mEHT) | Non-invasive 13.56 MHz modulated radiofrequency; selective cell membrane heating (40–42.5°C) | Deep-seated solid tumours (brain, pelvis, abdomen, thorax) alongside chemo or radiotherapy | Complementary therapy; cannot replace surgery or systemic chemotherapy |
| Conventional hyperthermia | Non-selective regional heating via microwave, ultrasound, or radiofrequency antennas | Superficial tumours (chest wall recurrences, melanoma, cervical cancer) | Risk of hotspot burns in healthy tissue; patient discomfort during deep heating |
| Radiofrequency ablation | Invasive needle electrode insertion; high-temperature coagulation necrosis (over 60°C) | Small, focal, well-defined tumours (liver, lung, kidney, bone lesions) | Limited to small lesions; invasive procedure with anaesthesia and bleeding risks |
Unlike oncothermia, which treats regional tumour tissue non-invasively, radiofrequency ablation delivers thermal energy invasively through a needle probe directly into small, isolated lesions to destroy tissue immediately. For patients evaluating focal thermal destruction versus regional modulation, our detailed guide on radiofrequency ablation explains needle-guided ablation criteria in detail.
Which solid tumours are treated with oncothermia?
Oncothermia is suitable for primary and secondary solid tumours where deep tissue penetration is needed while protecting overlying skin.
Common clinical applications include:
- Brain tumours: Recurrent high-grade gliomas and glioblastoma multiforme, usually combined with temozolomide chemotherapy.
- Gynaecological cancers: Locally advanced cervical, ovarian, and endometrial cancers receiving concurrent radiotherapy or platinum-based chemotherapy.
- Gastrointestinal malignancies: Inoperable pancreatic adenocarcinoma, gastric cancer, and colorectal liver metastases.
- Thoracic tumours: Locally advanced non-small cell lung cancer and malignant pleural mesothelioma.
- Pelvic and abdominal recurrences: Recurrent rectal tumours, bladder carcinoma, and soft-tissue sarcomas.
Oncothermia is not suitable for haematological cancers such as leukaemia or lymphoma, as circulating malignant cells cannot be targeted with localized capacitive fields.
Oncothermia before and after: what do scans show and realistic expectations
Understanding oncothermia results requires realistic expectations about tumour response kinetics. Thermal therapies do not produce overnight tumour disappearance.
Tumour necrosis and cellular breakdown occur gradually over weeks. Follow-up imaging—such as contrast-enhanced CT, MRI, or PET-CT—is typically performed 6 to 12 weeks after finishing a treatment cycle. In early scans, local inflammation and immune cell infiltration may cause treated tumours to appear stable or slightly enlarged, a known effect called pseudo-progression. PET-CT scans offer valuable clarity by measuring reduced glucose metabolism (FDG avidity), demonstrating reduced cancer cell viability before anatomical shrinkage appears.
Realistic goals include tumour stabilization, improved local disease control, enhanced chemotherapy or radiation response, pain reduction, and improved quality of life.
Who is a suitable candidate for oncothermia, and who is not?
Candidacy is evaluated by a multidisciplinary oncology board. Before travelling, medical records and imaging are reviewed by specialists in oncology care to verify clinical suitability.
Suitable candidates typically have:
- Histologically confirmed solid tumours that are locally advanced, inoperable, or recurrent.
- Concurrent chemotherapy, radiotherapy, or immunotherapy regimens that benefit from thermal sensitization.
- Good general performance status (ECOG score 0 to 2) allowing regular outpatient visits.
Contraindications include:
- Metallic implants in the treatment field: Cardiac pacemakers, defibrillators, surgical clips, or metal prostheses in the direct radiofrequency path, which can heat dangerously.
- Severe local fluid accumulation: Large ascites, severe pleural effusion, or pulmonary oedema within the target area.
- Pregnancy: Hyperthermia is strictly contraindicated during pregnancy.
- Severe organ failure: Decompensated cardiac or renal failure, active severe infection, or uncontrolled bleeding disorders.
Treatment schedule in Turkey and recovery milestones
For international patients, oncothermia is administered as an outpatient protocol in Turkey. A typical treatment cycle consists of 10 to 12 sessions scheduled two to three times weekly across two to four weeks.
Because the procedure is non-invasive and non-toxic, there is no physical recovery downtime. After a 60- to 90-minute session, you can leave the hospital immediately. Mild fatigue or gentle warmth may be felt for a few hours, but patients comfortably continue daily routines, take walks, and dine out. Hydration is encouraged to assist the clearance of cellular breakdown products. A medical review is conducted before departure, followed by scheduled remote consultations after you return home.
Risks, side effects and safety considerations of oncothermia
Oncothermia has an established safety profile with low toxicity compared with invasive interventions. Recognized hyperthermia guidelines from organizations like the European Society for Hyperthermic Oncology (ESHO) confirm it is well tolerated under proper clinical protocols.
Potential side effects are generally mild and localized:
- Skin redness: Transient superficial erythema under the electrode, resolving within hours.
- Subcutaneous fat sensitivity: Occasional tender nodules in deeper fat layers, which resolve spontaneously.
- Superficial blisters: Rare heat blisters if water bolus contact is uneven, prevented by continuous water cooling.
- Temporary fatigue: Mild systemic tiredness following energy delivery, manageable with rest and hydration.
- Local tumour ache: Temporary discomfort caused by increased blood flow and cellular stress.
How to choose an oncology clinic in Turkey and questions to ask
Choosing an oncology centre in Turkey requires careful verification. Ensure that oncothermia is delivered within a licensed, comprehensive hospital where medical oncologists, radiation oncologists, and medical physicists collaborate in multidisciplinary tumour boards, rather than in an isolated private office.
Be cautious of red flags: clinics promising that oncothermia can cure cancer alone, advice to discontinue standard chemotherapy or radiotherapy, lack of accredited oncologists, or opaque package quotes. Learn how our coordination process works when arranging specialist reviews. You can submit your medical reports through our free quote page for an oncologist-reviewed treatment plan.
Questions to ask the clinical team:
- Is the oncothermia system an approved medical device operated by qualified medical physicists?
- Will a multidisciplinary tumour board review my scans and treatment plan?
- How will hyperthermia sessions be synchronized with my chemotherapy or radiation schedule?
- What pre-treatment blood tests and imaging are conducted?
- How will my home oncology team be updated regarding my treatment summary?
Hospitals with Oncology in Turkey
Frequently asked questions
Oncothermia, or modulated electro-hyperthermia, is a non-invasive cancer therapy that applies a 13.56-megahertz radiofrequency current to solid tumours. It selectively heats malignant cell membranes to 40–42.5°C by exploiting their altered electrical impedance, triggering apoptosis while sparing healthy tissue. It is used alongside chemotherapy and radiotherapy.
Clinical trials show oncothermia works effectively as an adjunct therapy, improving local tumour control and progression-free survival when combined with radiotherapy or chemotherapy. It sensitises cancer cells to radiation and enhances drug uptake. However, it is not a standalone cure, and it cannot replace conventional oncological surgery or systemic therapies.
In Turkey, oncothermia costs approximately €200 to €500 per session, with a full 10-session protocol ranging from €2,000 to €4,800. In the UK, equivalent private sessions range between €600 and €1,400 each. The total price depends on tumour location, number of sessions, and whether systemic chemotherapy is administered concurrently.
Follow-up scans, usually performed 6 to 12 weeks post-treatment, evaluate metabolic activity and tumour size. PET-CT scans typically show reduced glucose uptake (FDG avidity), indicating decreased tumour viability. Routine CT or MRI may initially show pseudo-progression due to localized inflammation and necrosis before structural tumour shrinkage or stabilization becomes evident.
Recovery is virtually immediate because oncothermia is non-invasive and requires no anaesthesia. Each session lasts 60 to 90 minutes, after which patients can immediately resume light daily activities. Mild fatigue or temporary skin warmth may occur for a few hours, but there is no downtime or hospital admission required.
Oncothermia causes minimal discomfort. Patients lie comfortably on an ergonomic bed with water-cooled electrodes placed over the tumour site. You will feel a gentle, deep warming sensation during the session. The continuous circulation of cooled water prevents skin burning, and the power level can be adjusted immediately if any discomfort arises.
The cellular effects of oncothermia contribute to long-term tumour control when integrated into a broader treatment regimen. By inducing immunogenic cell death and enhancing chemotherapy or radiation response, it helps maintain local disease stabilization for months or years. Durability depends primarily on cancer stage, tumour biology, and ongoing systemic cancer management.
Oncothermia has a high safety profile. Common minor side effects include temporary skin redness, mild localized warmth, and transient fatigue. Rare risks include superficial heat blisters or localized fat tenderness under the electrode. It cannot be used in patients with cardiac pacemakers or metallic implants located within the electrical treatment field.
Oncothermia is a non-invasive regional therapy that heats tumours moderately (40–42.5°C) to sensitise them to chemotherapy and radiation. In contrast, radiofrequency ablation is an invasive surgical procedure that inserts needle electrodes directly into tumours, generating extreme heat (above 60°C) to burn and destroy small, isolated lesions permanently.
Most international patients stay in Turkey for two to four weeks. A standard treatment cycle consists of 10 to 12 sessions scheduled two or three times weekly. Clinics coordinate appointments on an outpatient basis, allowing you to rest comfortably in your hotel and explore the city between hospital visits.
Patient stories